SCHEMBL2124361

SCHEMBL2124361

CCCSc1c[nH]nc1-c1cccnc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.40
CYP2C19 P33261 3/20 0.40
CYP2D6 P10635 1/20 0.40
CYP19A1 P11511 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
CLK1 P49759 1/20 0.40
IDO1 P14902 1/20 0.39
LRRK2 Q5S007 1/20 0.39
KDM5A P29375 1/20 0.39
PIM1 P11309 3/20 0.39
MAP2K4 P45985 1/20 0.39
CYP2A6 P11509 2/20 0.39
CYP1A2 P05177 3/20 0.38
TDP1 Q9NUW8 1/20 0.37
NPY5R Q15761 1/20 0.37
ALK Q9UM73 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124589 0.92 CYP3A4 (0.45) CYP3A4CYP2C19CYP2D6CYP19A1CYP2C9
SCHEMBL2123555 0.91 CYP3A4 (0.44) CYP3A4CYP2C19CYP2D6CYP19A1CYP2C9
SCHEMBL2122612 0.90 CYP3A4 (0.43) CYP3A4CYP2C19CYP2D6CYP19A1CYP2C9
SCHEMBL2122454 0.89 ALDH1A1 (0.47) CYP3A4CYP2C19CYP2D6CYP19A1CYP2C9
SCHEMBL2125980 0.87 CYP2C19 (0.38) CYP3A4CYP2C19CYP2D6CYP19A1CYP2C9
SCHEMBL2122639 0.85 ALDH1A1 (0.38) CYP3A4CYP2C19CYP2C9ALDH1A1KDM4E
SCHEMBL2122057 0.83 MEN1 (0.41) CYP3A4ALDH1A1KDM4ELMNAHPGD
SCHEMBL2124594 0.82 CHRM2 (0.41) CYP3A4CYP2C19CYP2D6CYP19A1CYP2C9
SCHEMBL2121934 0.82 PKM (0.49) CYP3A4ALDH1A1KDM4ELMNAHPGD
SCHEMBL2124539 0.81 IDO1 (0.44) CYP3A4CYP2C19CYP2D6CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735388-B2 Heterocyclic compounds with affinity to muscarinic receptors ABBVIE B.V. (NL) 2014-05-27 US disclosed
US-20140080861-A1 HETEROCYCLIC COMPOUNDS IWTH AFFINITY TO MUSCARINIC RECEPTORS ABBVIE B.V.A (NL) 2014-03-20 US disclosed
US-8586606-B2 Heterocyclic compounds with affinity to muscarinic receptors ABBVIE B.V. (NL) 2013-11-19 US disclosed
US-20120095039-A1 HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS SOLVAY PHARMACEUTICALS B.V. 2012-04-19 US disclosed
US-8084473-B2 Heterocyclic compounds with affinity to muscarinic receptors SOLVAY PHARMACEUTICALS B.V. (NL) 2011-12-27 US disclosed
EP-2150543-A2 HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS Solvay Pharmaceuticals B.V. (NL) 2010-02-10 EP disclosed
US-20090018160-A1 Heterocyclic Compounds with Affinity to Muscarinic Receptors ABBVIE B.V. (NL) 2009-01-15 US disclosed
WO-2008129054-A2 HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS SOLVAY PHARMACEUTICALS B.V. (NL) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095039-A1 HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS CHRM3, CHRM5, CHRM2 CYP3A4 369/4885CYP2C19 482/4885CYP2D6 455/4885
US-20140080861-A1 HETEROCYCLIC COMPOUNDS IWTH AFFINITY TO MUSCARINIC RECEPTORS CHRM3, CHRM4, CHRM5 CYP3A4 392/4885CYP2C19 482/4885CYP2D6 409/4885
US-20090018160-A1 Heterocyclic Compounds with Affinity to Muscarinic Receptors CHRM3, CHRM2, CHRM1 CYP3A4 650/4885CYP2C19 1027/4885CYP2D6 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.